Björn Dahlöf

Medicine · Health Sciences

57h-index25.4kcitations249works24.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Pressure and Hypertension Studies(125), Cardiovascular Function and Risk Factors(58), Hormonal Regulation and Hypertension(53), Heart Rate Variability and Autonomic Control(39), Cardiac Imaging and Diagnostics(24)

Publications248 total

Abstract 4367586: Safety Profile of the CardioMEMS HF System in Pulmonary Arterial Hypertension: A Pooled Adverse Event Analysis from Three Clinical Studies
Circulation·2025
Abstract 4137045: Sustained Anti-Thrombotic Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential
Circulation·2024
CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis
European Heart Journal·2024
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
The Lancet Diabetes & Endocrinology·2024· 111 citedOpen Access
CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial
Pulmonary Circulation·2024· 9 citedOpen Access
CS585 Demonstrates Favorable Selectivity and Sustained <i>In Vivo</i> Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists
Blood·2023Open Access
HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of Bleeding
Blood·2023· 1 cited
Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosis
European Heart Journal·2023Open Access
HDAC inhibitor CS014 inhibits platelet activity, small and large vessel thrombosis while maintaining haemostasis in a dose-dependent manner
European Heart Journal·2023Open Access
The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
Blood·2023· 17 citedOpen Access
S309: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585
HemaSphere·2023Open Access
Abstract 122: The Eicosanoid Analogue Cs585 Represents A First-in-class In Prevention Of Platelet Activation And Thrombosis Through Direct Activation Of The Prostacyclin Receptor
Arteriosclerosis Thrombosis and Vascular Biology·2023
CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING
Journal of the American College of Cardiology·2023
CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding
European Heart Journal·2022Open Access
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
The Lancet·2022· 222 citedOpen Access
Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension
American Journal of Hypertension·2020· 7 citedOpen Access
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
Yearbook of pediatric endocrinology·2018· 18 cited
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Journal of the American Heart Association·2018· 12 citedOpen Access
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Deep Blue (University of Michigan)·2018
Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study
Blood Pressure·2016· 19 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Sverre E. Kjeldsen(19), Markku S. Nieminen(17), Richard B. Devereux(14), Kristian Wachtell(14), Hans Wedel(11), Lars Lindholm(11), Hans Ibsen(10), Peter M. Okin(10), Stevo Julius(9), Peter Sever(8), Neil R Poulter(8), Gareth Beevers(8), Michael Hecht Olsen(7), Richard B. Devereux(7), Eva Gerdts(7), Ulf dé Fairé(6), Jonathan M. Edelman(6), Thomas Unger(6), U. Muscha Steckelings(6), Vasilios Papademetriou(6)